5 results

An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children with Growth Hormone Excess
Gigantism is a condition characterized by excessive growth and height significantly above average, caused by over-production of growth hormone (GH) during childhood. Investigators at the National Institutes of Health (NIH) want to see if a drug that antagonizes growth hormone action, called pegvisomant, can help children and adolescents with gigantism.
Learn More

Children's Growth and Behavior Study
Researchers at the NIH Clinical Center are seeking healthy children for a study of growth and health behaviors. The purpose of the study is to better understand growth in children and adolescents.
Learn More